Physician profile
Henry S Chen
NPI 1093793101
$29,392.49
in general payments reported to CMS, 2019-2025
62 companies · $3,501 in 2025
The $3,501 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,166 · 2020: $3,194 · 2021: $6,177 · 2022: $3,430 · 2023: $3,472 · 2024: $3,453 · 2025: $3,501.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,425.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $3,170.25 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $3,149.04 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $1,935.15 | 2019-2025 | Trelegy Ellipta, Benlysta, Arexvy |
| Novo Nordisk INC | $1,925.50 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Merck Sharp & Dohme LLC | $1,682.27 | 2019-2025 | Verquvo, Capvaxive, Gardasil 9 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,473.59 | 2019-2025 | Jardiance, Cyltezo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,359.01 | 2019-2025 | Xifaxan, Trulance |
| Lilly USA, LLC | $1,290.56 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Abbvie INC. | $1,262.76 | 2019-2025 | Creon, Synthroid, Linzess |
| Pfizer INC. | $1,077.68 | 2019-2025 | |
| Biotronik INC. | $1,027.38 | 2019-2023 | Selectra |
| Novartis Pharmaceuticals Corporation | $856.69 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $847.65 | 2019-2024 | Xarelto |
| Amarin Pharma, INC. | $694.24 | 2019-2023 | |
| Azurity Pharmaceuticals, INC. | $684.75 | 2023-2025 | Horizant, Horizant, Alvesco |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Henry Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.